32 results
8-K/A
CMMB
Chemomab Therapeutics Ltd
14 Apr 21
UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS
11:50am
competitive; and
Chemomab’s reputation may suffer.
Any of these events could prevent Chemomab from achieving or maintaining market acceptance of a product … . Such events could have a material adverse effect on Chemomab’s reputation, business, financial condition or results of operations. Misappropriation
424B3
bqjar
12 Feb 21
Prospectus supplement
12:05pm
S-4/A
lij50w yh
10 Feb 21
Registration of securities issued in business combination transactions (amended)
1:19pm
S-4
02whxju 9ngoj
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
S-4
EX-10.4
ljs7dezq zs2d107
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
S-4
EX-10.3
4o4mm9x7q5 m5
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
DEF 14A
w6c99vpgvsoo7dkr
6 Apr 20
Definitive proxy
6:11am
PRE 14A
i189lnjlpg 44n
30 Mar 20
Preliminary proxy
5:03pm
10-K
ozt3k3cj 8kvrr8jytt
17 Mar 20
Annual report
5:27pm
S-8
EX-99.2
kbazmxs 71
22 Jul 19
Registration of securities for employees
5:17pm
6-K
EX-99.2
839snrn
28 May 19
Notice of Annual General Meeting of Shareholders of the Company
5:26pm
20-F/A
sp13v0e dh
24 Apr 19
Annual report (foreign) (amended)
5:19pm
424B4
20xcema x8v2egjos48
13 Feb 19
Prospectus supplement with pricing info
8:20am
F-1/A
xemwpzyuw9g ugclrn
11 Feb 19
Registration statement (foreign) (amended)
9:52am